Drug intelligence / Profile preview

BI 474121

Development stage: Phase 1
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Oral

Overview

BI 474121 is a potent and selective small molecule inhibitor of phosphodiesterase 2 (PDE2), developed by Boehringer Ingelheim. It is being investigated as an oral therapy for cognitive impairment associated with schizophrenia and Alzheimer's disease. By inhibiting PDE2, BI 474121 is expected to increase cyclic guanosine monophosphate (cGMP) levels in the central nervous system, which may improve cognitive function. The drug has demonstrated favorable safety and pharmacokinetic profiles in phase I clinical trials involving healthy volunteers from different populations[1][2][4][5][7].

Targets

PDE2 (Phosphodiesterase 2)

Beyond the preview

Go deeper on BI 474121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 474121.

Explore the full profile